← Back to screener

CORCEPT THERAPEUTICS INC CORT

Rank #1328 · Nasdaq · $8.7B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
49.8
P/E
82.0
P/B
17.35
ROE
21.2%
Op. Margin
22.2%
Debt Ratio
32%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E 82.0x, P/B 17.35x. Ranks in the top 72% of the universe.

Profitability ★★★★☆
Excellent

ROE 21.2%. Ranks in the top 19% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 32%. Ranks in the top 17% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★☆
Excellent

Revenue growth of 20.0% year over year. Ranks in the top 19% of the universe.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$-0.0B–-10389
2012–$-0.0B$-0.0B$0.0B–80
2013–$-0.0B$-0.0B$0.0B–367
2014–$-0.0B$-0.0B$0.0B–81
2015–$-0.0B$-0.0B$0.1B–-44
2016–$-0.0B$-0.0B$0.0B–147
2017–$-0.0B$-0.0B$-0.0B–-2129
2018$0.1B$0.0B$0.0B$0.0B12.5160
2019$0.2B$0.1B$0.1B$0.0B33.287
2020$0.3B$0.1B$0.1B$0.2B35.622
2021$0.3B$0.1B$0.1B$0.3B36.418
2022$0.4B$0.1B$0.1B$0.4B36.213
2023$0.4B$0.1B$0.1B$0.5B34.016
2024$0.4B$0.1B$0.1B$0.4B28.031
2025$0.5B$0.1B$0.1B$0.5B22.232

← See the full screener